LeMaitre Vascular (NASDAQ:LMAT) Updates Q3 2026 Earnings Guidance

LeMaitre Vascular (NASDAQ:LMAT) updated its third quarter 2026 earnings guidance on Tuesday morning. The company provided earnings per share guidance of 0.660-0.710 for the period, compared to the consensus estimate of 0.730. The company issued revenue guidance of $66.3 million-$68.3 million, compared to the consensus revenue estimate of $69.0 million. LeMaitre Vascular also updated its FY 2026 guidance to 2.840-2.940 EPS.

Wall Street Analyst Weigh In

A number of analysts have commented on the company. Weiss Ratings lowered LeMaitre Vascular from a “buy (b)” rating to a “buy (b-)” rating in a report on Tuesday, June 30th. Wall Street Zen cut LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Saturday. Citizens Jmp lifted their price objective on LeMaitre Vascular from $118.00 to $127.00 and gave the stock a “market outperform” rating in a report on Wednesday, May 6th. Barrington Research reissued an “outperform” rating and issued a $120.00 target price on shares of LeMaitre Vascular in a research report on Wednesday, June 3rd. Finally, Citigroup restated a “market outperform” rating on shares of LeMaitre Vascular in a research note on Tuesday, July 21st. Five investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $112.60.

LeMaitre Vascular Stock Performance

Shares of NASDAQ LMAT traded up $2.17 during midday trading on Tuesday, hitting $105.78. 405,320 shares of the stock traded hands, compared to its average volume of 255,427. The firm has a market capitalization of $2.42 billion, a P/E ratio of 39.03, a PEG ratio of 2.81 and a beta of 0.52. LeMaitre Vascular has a one year low of $79.39 and a one year high of $118.01. The company has a debt-to-equity ratio of 0.42, a quick ratio of 12.20 and a current ratio of 14.32. The firm has a 50-day moving average of $97.27 and a two-hundred day moving average of $99.90.

LeMaitre Vascular (NASDAQ:LMAT) last posted its quarterly earnings data on Tuesday, August 4th. The medical instruments supplier reported $0.74 EPS for the quarter, missing analysts’ consensus estimates of $0.81 by ($0.07). The firm had revenue of $70.38 million for the quarter, compared to analysts’ expectations of $71.47 million. LeMaitre Vascular had a net margin of 24.35% and a return on equity of 15.36%. On average, equities analysts forecast that LeMaitre Vascular will post 3 EPS for the current fiscal year.

Insider Transactions at LeMaitre Vascular

In other news, insider Trent G. Kamke sold 2,928 shares of the stock in a transaction that occurred on Friday, May 8th. The shares were sold at an average price of $107.00, for a total value of $313,296.00. Following the transaction, the insider owned 3,749 shares in the company, valued at $401,143. This represents a 43.85% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO George W. Lemaitre sold 27,881 shares of the firm’s stock in a transaction that occurred on Friday, May 8th. The stock was sold at an average price of $108.69, for a total transaction of $3,030,385.89. Following the completion of the transaction, the chief executive officer directly owned 1,430,019 shares in the company, valued at approximately $155,428,765.11. The trade was a 1.91% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 54,453 shares of company stock worth $5,906,174 in the last quarter. Company insiders own 7.40% of the company’s stock.

Institutional Investors Weigh In On LeMaitre Vascular

Hedge funds and other institutional investors have recently modified their holdings of the stock. Geneos Wealth Management Inc. raised its holdings in LeMaitre Vascular by 250.3% in the 1st quarter. Geneos Wealth Management Inc. now owns 557 shares of the medical instruments supplier’s stock worth $47,000 after purchasing an additional 398 shares during the period. EverSource Wealth Advisors LLC purchased a new stake in LeMaitre Vascular in the second quarter worth about $47,000. Quarry LP increased its position in LeMaitre Vascular by 267.2% in the third quarter. Quarry LP now owns 727 shares of the medical instruments supplier’s stock worth $64,000 after buying an additional 529 shares in the last quarter. Kestra Advisory Services LLC bought a new position in shares of LeMaitre Vascular in the fourth quarter worth about $68,000. Finally, Kemnay Advisory Services Inc. bought a new position in shares of LeMaitre Vascular in the fourth quarter worth about $80,000. 84.64% of the stock is currently owned by hedge funds and other institutional investors.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.